Skip to content
Open access

FDXR upregulation by p63/p73 is a prognostic and therapeutic marker of adult T-cell leukemia/lymphoma

Oct 2026 · EMBO Molecular Medicine · Vol 18, pp. 4529 - 4557 · 0 citations · 79 references
Medicine

TL;DR

The findings establish FDXR as a novel biomarker of HTLV-1-associated disease progression and ATL prognosis, elucidate its upstream molecular regulation, and highlight its predictive potential for chemotherapeutic sensitivity of ATL cells.

Abstract

Infection with HTLV-1 can lead to severe diseases, including adult T-cell leukemia/lymphoma (ATL), for which current therapies are inadequate. Selective elimination of chronically infected cells requires identifying cellular markers dysregulated by HTLV-1 that can be exploited therapeutically. Combining metabolomics and proteomics analyses, we identified increased expression of the mitochondrial enzyme ferredoxin reductase (FDXR) as a hallmark of HTLV-1-infected cells. In patient cells, FDXR upregulation mirrored disease severity, was enriched in proliferating tumour cells and predicted worse ATL prognosis. Mechanistically, FDXR upregulation in ATL cells is driven by the transactivating isoforms of two p53 family members, TAp63 and TAp73, and TAp63 expression is, in turn, induced by the IRF4/BATF3 transcriptional axis. In silico drug susceptibility predictions, followed by targeted cytotoxicity, proliferation and Drug-Seq assays demonstrated that FDXR upregulation is associated with increased sensitivity of ATL cells to repurposed chemotherapeutic agents, particularly fluorouracil. Overall, our findings establish FDXR as a novel biomarker of HTLV-1-associated disease progression and ATL prognosis, elucidate its upstream molecular regulation, and highlight its predictive potential for chemotherapeutic sensitivity of ATL cells. Human T-cell lymphotropic virus 1 can cause adult T-cell leukemia/lymphoma (ATL), which is prone to chemoresistance and relapse. FDXR is identified as a biomarker of ATL progression and chemosensitivity. FDXR upregulation in patient-derived cells mirrors the severity of HTLV-1-associated disease. Elevated FDXR levels are linked to worse ATL prognosis. FDXR upregulation in HTLV-1+/ATL cells is driven by a pathway converging on two p53 family members, p63 and p73. Higher basal or drug-induced FDXR expression is associated with increased sensitivity of ATL cells to fluorouracil and bleomycin. FDXR upregulation in patient-derived cells mirrors the severity of HTLV-1-associated disease. Elevated FDXR levels are linked to worse ATL prognosis. FDXR upregulation in HTLV-1+/ATL cells is driven by a pathway converging on two p53 family members, p63 and p73. Higher basal or drug-induced FDXR expression is associated with increased sensitivity of ATL cells to fluorouracil and bleomycin. Human T-cell lymphotropic virus 1 can cause adult T-cell leukemia/lymphoma (ATL), which is prone to chemoresistance and relapse. FDXR is identified as a biomarker of ATL progression and chemosensitivity.

Read PDF

Similar papers

Open access May 2026

Selumetinib Inhibits T-Acute Lymphoblastic Leukemia Cell Proliferation by Inducing Apoptosis, Inhibiting Autophagy, and Modulating Reactive Oxygen Species Pathway

Background: Early relapse and a poor prognosis are standard features of T-acute lymphoblastic leukemia (T-ALL), a hematological malignancy that presents significant treatment challenges. Glucocorticoids (GCs) are the first line of treatment for T-ALL; nevertheless, GC resistance may develop in patients with newly diagn...

Faezeh Bagherifar, J. Ahmadi, P. Hamedi-Asl et al. · 0 citations
Open access Oct 2026

Exonuclease 1 drives immune escape in lung adenocarcinoma by regulating the HIF-1α/PD-L1 axis

Lung Adenocarcinoma (LUAD) represents the most prevalent subtype of lung cancer and additionally possesses the highest potential for lethality. EXO1 is overexpressed in multiple cancers and linked to poor prognosis, but its role in LUAD immune regulation remains unclear. Immunosuppression can be stimulated by HIF-1α, w...

Chun-Yan Gao, Lu-Lu Zhang, Bi-Wei Gao et al. · 0 citations
Review Open access Nov 2026

SLC7A11/GPX4-dependent resistance to ferroptosis induction in acute myeloid leukemia cells: molecular markers and therapeutic prospects

The review presents an analysis of current literature data on the role of iron-dependent regulated cell death (ferroptosis) in the pathogenesis of acute myeloid leukemia (AML). The molecular mechanisms of SLC7A11/GPX4-dependent resistance of leukemic cells to ferroptosis induction are discussed, including transcription...

C. A. Geldimammedov, A. N. Koval, A. V. Litvinchuk et al. · 0 citations
Review Open access Oct 2026

Unraveling Vulnerabilities and Pathways Responsible for AITL Malignancy to Improve Patients’ Treatment

Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive subtype of peripheral T-cell lymphoma characterized by poor clinical outcomes following conventional CHOP-based chemotherapy and the lack of effective disease-specific therapeutic options. The disease finds its origin in CD4 follicular helper T (Tfh) cells and...

C. Martinello, Adrien Krug, Pau Marin-Escudero et al. · 0 citations
Oct 2026

NFS1 as a Metabolic Vulnerability in Acute Myeloid Leukemia Through Iron Dysregulation and STAT1/IFIT2-Associated Signaling.

Acute myeloid leukemia (AML) is a metabolically heterogeneous malignancy with poor outcomes and limited durable therapeutic options. We investigated NFS1, a key enzyme involved in iron-sulfur cluster biogenesis, as a potential metabolic vulnerability in AML. NFS1 was overexpressed in AML samples, and higher expression...

Ying Liu, Zi-Yi Wei, Bing-Xin Qian et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.